Innovations in the Radiotherapy of Non–Small Cell Lung Cancer

Schild, Steven E.; Bogart, J.A.

doi:10.1016/s1556-0864(15)31520-3

Cited by 7 publications

(5 citation statements)

References 47 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In extension to this result, it is recommended when implementing new innovations in RT for lung cancer [28,29] such as intensitymodulated RT, tomotherapy, stereotactic RT or particle therapy, to carefully monitor the QoL of patients, in order to evaluate this prognostic factor and the impact of the new technology.…”

Section: Discussionmentioning

confidence: 99%

High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL

Pijls‐Johannesma

Houben

Boersma

et al. 2009

Radiotherapy and Oncology

View full text Add to dashboard Cite

a b s t r a c tBackground and purpose: Aggressive radiotherapy or concurrent chemo-radiation therapy for lung cancer leads to a high incidence of severe, mostly esophageal, toxicity. The purpose of this study was to investigate the evolution of quality of life (QoL) in patients with lung cancer, selected for curative radiotherapy (RT) or chemo-RT. Methods: Seventy-five lung cancer patients completed a longitudinal the EORTC QLQ-C30 and LC13. Linear mixed regression models were fitted to investigate the impact of different factors on overall QoL. Results: Overall QoL decreased shortly after the end of RT (4 points, p = 0.19), but increased back to baseline within 3 months. Mean scores of role functioning (p = 0.018), cognitive functioning (p = 0.002), dyspnoea (EORTC QLQ-LC13; p = 0.043), dysphagia (p = 0.005) and hoarseness (p = 0.029), showed a significant worsening over time. Emotional functioning (p = 0.033) improved significantly over time. Severe esophagitis (Pgrade 2) was reported in only 12% of the patients. Next to maximal esophageal toxicity Pgrade 2 (p = .0.010), also tumor stage IIIA (p < 0.001), tumor stage IIIB (p = 0.003), gender (p = 0.042) and fatigue (p < 0.001) appeared to be significant predictors of QoL. Conclusion: High-dose radiotherapy or concurrent chemo-radiation in the treatment of lung cancer seems to be a well-tolerated treatment option with preservation of QoL. Lung cancer remains a major public health problem worldwide because of its high incidence, rapid progression, and poor outcome [1]. The majority of patients who develop lung cancer die of this disease within a year [2]. Aggressive radiotherapy or concurrent chemo-radiation therapy for lung cancer is standard care for patients with locally advanced disease, i.e. stage III non-small cell lung cancer (NSCLC) or limited stage small cell lung carcinoma (LD-SCLC) [3,4].Combined concurrent modality treatment increases long-term survival, but at the expense of a higher incidence of severe esophagitis [5][6][7][8]. In order to allow proper balancing between expected benefits and drawbacks of aggressive therapy, knowledge of the effects of a given treatment on the quality of life (QoL) is needed.An optimal therapy could be defined as one that increases survival or provides benefit through reduction in cancer-related symptoms and improved QoL.To the best of our knowledge, in only one study, QoL assessment was performed in patients receiving high-dose radiotherapy for NSCLC [9]. No data are at present known on the influence of concurrent chemo-radiation on the QoL.Moreover, a broad Medline search using the terms ''QoL and SCLC" (December 2008) revealed only 15 studies of which none examined QoL after radiotherapy treatment.The purpose of this study was to investigate the evolution of QoL on NSCLC stages I-III and LD-SCLC patients, referred for hyperfractionated accelerated high-dose radiotherapy (RT) with or without concurrent chemotherapy, with curative intent. Since we hypothesized that QoL would be considerably influenced by esophageal...

show abstract

Section: Discussionmentioning

confidence: 99%

High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL

Pijls‐Johannesma

Houben

Boersma

et al. 2009

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…1,2 These results were quite inferior to those achieved with surgery. 3,4 Recently, new modalities 5 such as stereotactic radiotherapy 6,7 and proton radiotherapy 8,9 have been tried but have not yet been demonstrated as valid alternatives.…”

mentioning

confidence: 99%

Carbon Ion Radiotherapy for Stage I Non-small Cell Lung Cancer Using a Regimen of Four Fractions during 1 Week

Miyamoto¹,

Baba²,

Sugane³

et al. 2007

Journal of Thoracic Oncology

169

109

View full text Add to dashboard Cite

show abstract

“…With modern treatment planning, we could expect a higher MTD, possibly a different profile of side effects, and improved tumor control. 27,28 Anemia is the third area for potential improvement of our results. Mean hemoglobin levels were 116 g/L after induction chemotherapy and 93 g/L at the nadir during concurrent chemotherapy/radiotherapy.…”

confidence: 94%

Gemcitabine, Cisplatin, and Hyperfractionated Accelerated Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Zwitter

Kovač

Smrdel

et al. 2006

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Innovations in the Radiotherapy of Non–Small Cell Lung Cancer

Cited by 7 publications

References 47 publications

High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL

High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL

Carbon Ion Radiotherapy for Stage I Non-small Cell Lung Cancer Using a Regimen of Four Fractions during 1 Week

Gemcitabine, Cisplatin, and Hyperfractionated Accelerated Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Contact Info

Product

Resources

About